All In Biotech

Drug Trial Radar · NCT07387003

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

A Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs or Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 345 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

345

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Feb 11, 2027

Study completion Sep 23, 2027

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.

Conditions

  • Type 2 Diabetes (T2DM)

Interventions

  • GZR101-80Drug

    Administered SC

  • GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)Drug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin A1c (HbA1c) from baseline after 16 weeks of treatment.Time frame: Baseline , 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.